Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice